藤原 篤之
   Department     ,
   Position  
Article types 原著
Language English
Peer review Peer reviewed
Title Impact of Polyp Regression on 2-year Outcomes of Intravitreal Aflibercept Injections: A Treat-and-Extend Regimen for Polypoidal Choroidal Vasculopathy.
Journal Formal name:Acta medica Okayama
Abbreviation:Acta Med Okayama
ISSN code:0386300X/0386300X
Domestic / ForeginForegin
Volume, Issue, Page 72(4),379-385頁
Author and coauthor Morizane-Hosokawa Mio, Morizane Yuki, Kimura Shuhei, Shiode Yusuke, Hirano Masayuki, Doi Shinichiro, Toshima Shinji, Hosogi Mika, Fujiwara Atsushi, Shiraga Fumio
Publication date 2018/08
Summary We conducted intravitreal aflibercept injections (IVAs) for 37 Japanese patients (28 males, 9 females, mean age 73.4 years) with polypoidal choroidal vasculopathy (PCV), with a treat-and-extend regimen (TER). We evaluated the impact of polyp regression after a loading dose (2-mg IVA 1×/month for 3 months) on the patients' 2-year treatment outcomes. Thirty-seven eyes were treated with IVA by a TER for 2 years. We divided the patients into 2 groups based on their polyp status after the loading dose: polyp regression (PR+) (n=19) and no polyp regression (PR-) (n=18). We compared the groups' best-corrected visual acuity (BCVA), central retinal thickness (CRT), recurrence rate, total number of injections, and final treatment interval. Both the BCVA and CRT were significantly improved by the treatment in both groups, with no between-group difference in the amount of change (p=0.769). In the polyp regression (+) group, recurrence was significantly less common (p=0.03), the mean total number of injections was significantly lower (p=0.013), and the mean treatment interval was significantly longer (0.042). Regarding the 2-year outcomes for PCV, the eyes with post-loading-dose polyp regression demonstrated less frequent recurrence and required fewer numbers of injections compared to the eyes without polyp regression.
DOI 10.18926/AMO/56175
PMID 30140086